Medicine and Dentistry
Neoplasm
100%
Head and Neck Cancer
56%
Malignant Neoplasm
56%
Lung
52%
Radiation Therapy
45%
Radiation Therapy Planning
40%
Protein P53
34%
Intensity Modulated Radiation Therapy
34%
Non Small Cell Lung Cancer
34%
Diseases
32%
Dysplasia
31%
Recurrent Disease
26%
Head and Neck Squamous Cell Carcinoma
26%
Computer Assisted Tomography
25%
Tumor Cell
22%
Pulmonary Toxicity
20%
Single-Photon Emission Computed Tomography
20%
Mouth Squamous Cell Carcinoma
19%
Precancerous Condition
19%
Carcinoma
19%
Cancer
19%
Cancer Research
17%
Lung Cancer
17%
Angiogenesis Inhibitor
17%
N (4 Bromo 2 Fluorophenyl) 6 Methoxy 7 [2 (1h 1,2,3 Triazol 1 Yl)ethoxy] 4 Quinazolinamine
17%
Magnetic Resonance Imaging
17%
Oral Mucosa
17%
Epigenomics
17%
Oncofetal Antigen
17%
Case-Control Study
17%
Gene Transfer
17%
Biological Marker
17%
Immune Response
17%
Positron Emission Tomography-Computed Tomography
17%
Allelic Imbalance
17%
Adenoviridae
17%
Cytokine Receptor
17%
Molecular Marker
17%
Conformal Radiotherapy
16%
Mouth Lesion
14%
Focal Adhesion
13%
Functional Imaging
11%
Precursor
11%
Squamous Cell Carcinoma
10%
Minimal Residual Disease
10%
Primary Tumor
10%
Diagnostic Imaging
8%
Clinical Trial
8%
Cancer of Unknown Primary Origin
8%
Gastrocnemius
8%
Biochemistry, Genetics and Molecular Biology
Allelic Imbalance
52%
Microsatellite
38%
Precursor
37%
Clonal Variation
26%
P53
26%
Allele
26%
Clonality
26%
Genetics
17%
Wild Type
17%
Case-Control Study
17%
Morphology
17%
Tumor Volume
17%
Mucosa
14%
Dysplasia
13%
Chromosome Arm
8%
Vascularization
8%
Genotyping
8%
Angiogenesis
8%
Lung Perfusion
6%
Carcinogenesis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
34%
Radioisotope
34%
Dosimetry
23%
Head and Neck Cancer
21%
Dysplasia
19%
Diseases
17%
Recurrent Disease
17%
Precancer
17%
Head and Neck Carcinoma
17%
Molecular Marker
17%
N (4 Bromo 2 Fluorophenyl) 6 Methoxy 7 [2 (1h 1,2,3 Triazol 1 Yl)ethoxy] 4 Quinazolinamine
17%
Protein P53
17%
Biological Marker
17%
Neoplasm
15%
Squamous Cell Carcinoma
10%
Inflammation
8%
Malignant Transformation
8%
Mouth Lesion
8%
Clinical Trial
8%
Long Term Survival
8%